Tivozanib
Back to searchMolecule Structure
Scientific Name
Tivozanib
Description of the Drug
Tivozanib is a kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11800
http://www.drugbank.ca/drugs/DB11800
Brand Name(s)
Fotivda
Company Owner(s)
Aveo Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Platelet-derived growth factor receptor beta | SINGLE PROTEIN | INHIBITOR | CHEMBL1913 |
Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL172883 |
Human Metabolome Database | HMDB0304847 |
DrugBank | DB11800 |
PubChem: Thomson Pharma | 14882223 |
PubChem | 9911830 |
LINCS | LSM-1005 |
Nikkaji | J2.121.508B |
PDBe | AV9 |
BindingDB | 50331095 |
DrugCentral | 5258 |
ChemicalBook | CB82484655 |
Guide to Pharmacology | 6058 |
ChEBI | 91327 |
ZINC | ZINC000001489430 |